(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol

Sotagliflozin is an S-glycosyl compound that is 1-thio-beta-L-xylopyranose in which the anomeric hydroxy group is replaced by a 4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl group and the thiol is replaced by a methylsulfanediyl group. It is an inhibitor of SGLT1 and SGLT2 that is approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk. It has a role as a sodium-glucose transport protein subtype 1 inhibitor, a hypoglycemic agent, an antihypertensive agent, a sodium-glucose transport protein subtype 2 inhibitor and a cardioprotective agent. It is a C-glycosyl compound, a S-glycosyl compound, an aromatic ether and a member of monochlorobenzenes.

Disclaimer: The information above is provided for general reference purposes only. Applications, dosage, handling procedures and suitability for any specific use must be determined solely by the user based on their own assessment. This information does not constitute a recommendation or endorsement for any particular application and should not be used as the basis for product selection.